**Core Concept**
The NPC1L1 receptor is a protein expressed in the small intestine, responsible for the uptake of cholesterol from the intestinal lumen. Certain antilipidemic drugs target this receptor to reduce cholesterol absorption.

**Why the Correct Answer is Right**
The antilipidemic drug ezetimibe specifically binds to the NPC1L1 receptor, preventing the uptake of cholesterol from the intestinal lumen. This results in reduced cholesterol levels in the bloodstream, as less cholesterol is absorbed from the diet. Ezetimibe acts independently of bile acid sequestration and HMG-CoA reductase inhibition, making it a useful adjunct to statin therapy in managing hyperlipidemia.

**Why Each Wrong Option is Incorrect**
**Option A:** Fenofibrate is a fibric acid derivative that works by activating PPAR-alpha, leading to increased lipolysis and clearance of triglyceride-rich lipoproteins. It does not act on NPC1L1 receptors.
**Option B:** Atorvastatin is a statin that inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis. It does not reduce cholesterol absorption in the intestine.
**Option C:** Colestipol is a bile acid sequestrant that works by binding to bile acids in the intestine, preventing their reabsorption and thereby increasing the conversion of cholesterol to bile acids. It does not act on NPC1L1 receptors.

**Clinical Pearl / High-Yield Fact**
Ezetimibe is often used in combination with statins to achieve greater reductions in LDL cholesterol levels, as it targets a different step in the cholesterol absorption pathway.

**Correct Answer: C. Ezetimibe**